France Breast Cancer Therapeutics Market Report 2022 to 2030

France Breast Cancer Therapeutics Market Analysis

$ 3999

This report presents a strategic analysis of the France Breast Cancer Therapeutics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the France Breast Cancer Therapeutics Market, offering unmatched value, accuracy and expert insights.

ID: IN10FRPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: France

Buy Now

France Breast Cancer Therapeutics Executive Summary

In 2020, France spent 209.2 billion euros on healthcare, or almost 3,100 euros per person. In 2019, health spending accounted for 11.1 percent of GDP, matching Germany as the largest share in the EU. In response to the COVID-19 issue, public health spending increased by 9.5 percent in 2020, while GDP fell by 8%. Every year, more than 1,000 clinics and private hospitals in France contribute to the care of nine million patients. These facilities do 55% of surgical procedures, two-thirds of day surgery, a quarter of mental hospitalizations, and 20% of births (FHP). In addition, there are 4,700 private non-profit organizations in France that treat 2.5 million people each year.

The pharmaceutical industry covers all aspects of medication research, development, production, and distribution. Pharma revenues worldwide reached $1.42 trillion in 2021 due to the market's rapid growth over the previous two decades. With the introduction of new technology as well as more economical and effective manufacturing techniques, the industry has experienced a significant transition. Additionally, the market growth has been positively driven by rising investment flow in this sector.

Cancer is essentially the uncontrolled growth of certain cells in the body that crowd out normal cells over time. Breast cancer may develop when breast cells start to grow out of control. These cells generally form a tumor that can be felt as a lump, which can further be confirmed using a mammogram. The tumor is malignant if the cells can grow into surrounding tissues or spread to other parts of the body. Breast cancer occurs almost entirely in women, though men can also contract breast cancer. Mutations in DNA can cause normal breast cells to become cancerous cells. Some DNA changes are passed on from parents and can significantly increase the threat of breast cancer.

The Europe Breast Cancer Therapeutics market is estimated to be valued at US$ 8.2 Bn in 2021 and is expected to exhibit a CAGR of 7.1% over the forecast period (2021-2030).

France Breast Cancer Therapeutics Size (In USD Bn) (2021-2030F)

Market Dynamics

Market Growth Drivers Analysis

The increased incidence of breast cancer around the world, which is anticipated to lead to a sizable patient population demanding precise and effective treatment options, is one of the key factors driving the growth of the France market. Breast cancer is one of the most common types of cancer in the world, and more patients are anticipated to be diagnosed as a result of improved diagnostics.

Market Restraints

In the near future, adverse reactions to breast cancer treatments, such as targeted therapies, may restrain market expansion. For e.g., the American Cancer Society (ACS) reports that a number of side effects are associated with targeted therapies, including high blood pressure, gastrointestinal issues like diarrhea, and skin issues. The patient might not be able to use that particular medication in cases of severe adverse reactions and might need to switch to alternative therapeutic modalities.

Competitive Landscape

Key Players

The prominent players operating in this market include Genentech (US), AstraZeneca (UK), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi (France), Kyowa Kirin (Japan), Eisai Co. Ltd. (Japan), Merck & Co. Inc. (US) and Amgen (US)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.